* Cabaletta Bio Inc CABA.OQ CABA.O is expected to show
no
change in quarterly revenue when it reports results on November
7 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Cabaletta Bio Inc is for
a
loss of 60 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cabaletta
Bio Inc
is $24.00, above its last closing price of $4.20.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.56 -0.55 -0.56 Missed -2.2
Mar. 31 2024 -0.47 -0.48 -0.51 Missed -7.2
Jan. 1 0001 -0.40 -0.39 -0.46 Missed -17.2
Sep. 30 2023 -0.41 -0.40 -0.37 Beat 8.3
Jun. -0.44 -0.44 -0.37 Beat 16.4
30 2023
Mar. 31 2023 -0.48 -0.48 -0.45 Beat 6.3
Dec. 31 2022 -0.48 -0.45 -0.52 Missed -15.1
Jan. 1 0001 -0.47 -0.48 -0.39 Beat 19
This summary was machine generated November 6 at 14:18 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)